Ask AI
ProCE Banner Activity

KRAS-Mutated Low-Grade Serous Ovarian Cancer

Slideset

Download these slides covering the evidence supporting the recent approval of dual MEK/FAK inhibition for patients with KRAS-mutated low-grade serous ovarian cancer (LGSOC) including the use of biomarker testing to guide optimal treatment selection in patients with LGSOC and integrating recent data and managing AEs associated with new agents. 

Released: February 17, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Verastem, Inc.

Verastem, Inc.

Target Audience

This activity has been designed to meet the educational needs of oncologists, nurse practitioners, physician associates, pharmacists, and other healthcare professionals who manage patients with ovarian cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate biomarker testing into clinical practice to guide treatment of targeted agents in patients with KRAS-mutated low-grade serous ovarian cancer

  • Align clinical practice with recent key data and approvals supporting the use of dual MEK/FAK targeting in patients with KRAS-mutated low-grade serous ovarian cancer

  • Manage adverse events associated with MEK/FAK-targeted agents in patients with low-grade serous ovarian cancer

Faculty Disclosure

Primary Author

Rachel Grisham, MD: consultant/advisor/speaker: AstraZeneca, GSK, Incyclix, Incyte, SpringWorks; other financial or material support: Verastem.